{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:41:07Z","timestamp":1788716467310,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s12664-023-01434-9","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T03:27:18Z","timestamp":1695180438000},"page":"237-243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Upfront tofacitinib in patients with biological-na\u00efve ulcerative colitis \u2013 An Indian multicentric experience"],"prefix":"10.1007","volume":"43","author":[{"given":"Suprabhat","family":"Giri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukanya","family":"Bhrugumalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Kamuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debakanta","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish Kumar","family":"Pati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhiraj","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govind","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Wagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamshersingh","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghraj","family":"Ingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Chandnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin M.","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6925-0214","authenticated-orcid":false,"given":"Aditya","family":"Kale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"1434_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical treatment. J Crohns Colitis. 2022;16:2\u201317.","journal-title":"J Crohns Colitis"},{"key":"1434_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/gast.2001.26279","volume":"121","author":"WA Faubion Jr","year":"2001","unstructured":"Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255\u201360.","journal-title":"Gastroenterology"},{"key":"1434_CR3","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","volume":"17","author":"WJ Sandborn","year":"2019","unstructured":"Sandborn WJ, Pan\u00e9s J, D\u2019Haens GR,\u00a0 et al. Safety of Tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from Global Clinical Trials. Clin Gastroenterol Hepatol. 2019;17:1541\u201350.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"1434_CR4","doi-asserted-by":"crossref","first-page":"175628481984863","DOI":"10.1177\/1756284819848631","volume":"12","author":"F D'Amico","year":"2019","unstructured":"D\u2019Amico F, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol. 2019;12:1756284819848631.","journal-title":"Therap Adv Gastroenterol"},{"key":"1434_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/ecco-jcc\/jjy114","volume":"13","author":"A Sturm","year":"2019","unstructured":"Sturm A, Maaser C, Calabrese E, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis. 2019;13:273\u201384.","journal-title":"J Crohns Colitis."},{"key":"1434_CR6","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","volume":"11","author":"M Harbord","year":"2017","unstructured":"Harbord M, Eliakim R, Bettenworth D,\u00a0 et al. European Crohn\u2019s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current management. J Crohn\u2019s Colitis. 2017;11:769\u201384.","journal-title":"J Crohn\u2019s Colitis."},{"key":"1434_CR7","volume":"2","author":"MK Dalai","year":"2023","unstructured":"Dalai MK, Ingle M, Singh G, Pandey V, Chauhan S, Bairwa Y. A case of tofacitinib induced mania. Psych Res Case Rep. 2023;2: 100114.","journal-title":"Psych Res Case Rep"},{"key":"1434_CR8","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1093\/ibd\/izab087","volume":"27","author":"A Jena","year":"2021","unstructured":"Jena A, Mishra S, Sachan A, Singh H, Singh AK, Sharma V. Tofacitinib in acute severe ulcerative colitis: Case series and a systematic review. Inflamm Bowel Dis. 2021;27:e101\u20133.","journal-title":"Inflamm Bowel Dis"},{"key":"1434_CR9","doi-asserted-by":"publisher","first-page":"i111","DOI":"10.1093\/ecco-jcc\/jjac190.0084","volume":"17","author":"A Singh","year":"2023","unstructured":"Singh A, Midha V, Mahajan R, Kaur K, Singh D, Sood A. DOP44 Tofacitinib versus corticosteroids for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective randomized open-label pilot study. J Crohns Colitis. 2023;17:i111\u20132.","journal-title":"J Crohns Colitis"},{"key":"1434_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/ibd\/izab011","volume":"28","author":"C Taxonera","year":"2022","unstructured":"Taxonera C, Olivares D, Alba C. Real-World effectiveness and safety of Tofacitinib in patients with ulcerative colitis: Systematic review with meta-analysis. Inflamm Bowel Dis. 2022;28:32\u201340.","journal-title":"Inflamm Bowel Dis"},{"key":"1434_CR11","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.cgh.2020.10.038","volume":"20","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, Peyrin-Biroulet L, Quirk D, et al. Efficacy and safety of extended induction with Tofacitinib for the treatment of ulcerative colitis. Clin Gastroenterol Hepatol. 2022;20:1821-30.e3.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1434_CR12","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjaa075","volume":"14","author":"S Honap","year":"2020","unstructured":"Honap S, Chee D, Chapman TP, et al. Real-world effectiveness of Tofacitinib for moderate to severe ulcerative colitis: A multicentre UK experience. J Crohns Colitis. 2020;14:1385\u201393.","journal-title":"J Crohns Colitis."},{"key":"1434_CR13","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Park SH, Gul A,\u00a0 et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1133\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1434_CR14","doi-asserted-by":"publisher","first-page":"S274","DOI":"10.1093\/ecco-jcc\/jjy222.468","volume":"13","author":"R Ungaro","year":"2019","unstructured":"Ungaro R, Fenster M, Dimopoulos C, et al. Real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study. J Crohns Colitis. 2019;13:S274\u20135.","journal-title":"J Crohns Colitis"},{"key":"1434_CR15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40273-023-01254-x","volume":"41","author":"T Kobayashi","year":"2023","unstructured":"Kobayashi T, Hoshi M, Yuasa A, et al. Cost-efmfectiveness analysis of Tofacitinib compared with biologics in biologic-na\u00efve patients with moderate-to-severe ulcerative colitis in Japan. Pharmacoeconomics. 2023;41:589\u2013604.","journal-title":"Pharmacoeconomics"},{"key":"1434_CR16","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/ibd\/izab278","volume":"28","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, Armuzzi A, Liguori G,\u00a0 et al. Predictors of sustained response with Tofacitinib therapy in patients with ulcerative colitis. Inflamm Bowel Dis. 2022;28:1338\u201347.","journal-title":"Inflamm Bowel Dis"},{"key":"1434_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/13696998.2021.1881323","volume":"24","author":"A Sardesai","year":"2021","unstructured":"Sardesai A, Dignass A, Quon P,\u00a0 et al. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany. J Med Econ. 2021;24:279\u201390.","journal-title":"J Med Econ"},{"key":"1434_CR18","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/ecco-jcc\/jjaa249","volume":"15","author":"S Vermeire","year":"2021","unstructured":"Vermeire S, Su C, Lawendy N,\u00a0 et al. Outcomes of Tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised RIVETING Trial. J Crohns Colitis. 2021;15:1130\u201341.","journal-title":"J Crohns Colitis"},{"key":"1434_CR19","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1007\/s10620-021-07233-6","volume":"67","author":"N Ishida","year":"2022","unstructured":"Ishida N, Miyazu T, Tamura S,\u00a0 et al. Real-world efficacy and safety monitoring for predicting continuation of Tofacitinib therapy in patients with ulcerative colitis. Dig Dis Sci. 2022;67:3984\u201392.","journal-title":"Dig Dis Sci"}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-023-01434-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-023-01434-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-023-01434-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T23:04:55Z","timestamp":1709939095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-023-01434-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1434"],"URL":"https:\/\/doi.org\/10.1007\/s12664-023-01434-9","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,20]]},"assertion":[{"value":"5 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SG, SB, AbK, DM, GKP, DA, GV, RW, SsC, MI, SC, SJ, PMR, AS and AK declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed conforming to the Helsinki Declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Taken from respective Institutional Ethical Committees.Ethical clearance was taken from IEC of respective centers.Coordinating center: Nizam's Institute of Medical Sciences: EC\/NIMS\/4157\/2023.Other centers:Lokmanya Tilak Municipal General Hospital and Medical College: IEC\/26\/23.Seth GS Medical College and KEM Hospital: EC\/OA-70\/2023.The other three centers received an exemption from the IEC due to the study\u2019s retrospective nature, with a sample size of less than five from each center and only written informed consent was taken from the participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No funds, grants or other support were received.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosures"}},{"value":"The authors are solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology\u00a0or the printer\/publishers are responsible for the results\/findings and content of this article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}